Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarctionThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet.
- 1 April 2008
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 86 (4) , 180-189
Abstract
Antiplatelet agents such as sarpogrelate (SAR), a 5-hydroxytryptamine antagonist, and cilostazol (CIL), a phosphodiesterase-III inhibitor, are used in the management of peripheral vascular disease. In this study, we tested the hypothesis that both SAR and CIL prevent cardiac remodeling and improve cardiac function in congestive heart failure (CHF) due to myocardial infarction (MI). Post-MI rats (3 weeks after the occlusion of coronary artery) received either vehicle (MI+V, n = 36), SAR (MI+SAR; 5 mg·kg–1·day–1, n = 35) or CIL (MI+CIL; 5 mg·kg–1·day–1, n = 34) from day 21 to day 56. Sham-operated rats (n = 29) served as controls. Electrocardiographic, echocardiographic, and hemodynamic parameters were measured on day 56. Treatment of infarcted animals with SAR or CIL significantly improved the left ventricular (LV) dimensions, LV fractional shortening, cardiac output, stroke volume, mean arterial pressure, LV diastolic function, and LV systolic pressure, as well as rates of LV pressure development and pressure decay. Although cardiac hypertrophy was reduced, both SAR and CIL had no effect on infarct size or MI-associated QTc prolongation. However, SAR decreased whereas CIL increased the incidence of ventricular arrhythmias and the mean number of episodes in infarcted animals. Mortality during the treatment period was decreased by 17% with SAR and increased by 10% with CIL, but these changes were not significant statistically. The data in this study suggest that both SAR and CIL prevent cardiac remodeling and improve cardiac function in MI-induced CHF; however, CIL unlike SAR increased the incidence of arrhythmias and adversely affected patient mortality.Keywords
This publication has 32 references indexed in Scilit:
- Sarpogrelate: cardiovascular and renal clinical potentialExpert Opinion on Investigational Drugs, 2004
- Sarpogrelate treatment reduces restenosis after coronary stentingAmerican Heart Journal, 2003
- Changes in Plasma Serotonin Concentration and Acceleration Plethysmograms in Patients with Raynaud's Phenomenon after Long‐term Treatment with a 5‐HT2 Receptor AntagonistThe Journal of Dermatology, 2000
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureNew England Journal of Medicine, 1998
- Serotonin enhances the production of type IV collagen by human mesangial cellsKidney International, 1998
- Rate of Collagen Deposition During Healing and Ventricular Remodeling After Myocardial Infarction in Rat and Dog ModelsCirculation, 1996
- Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat.Circulation, 1994
- Estimation of left ventricular end-diastolic pressure from Doppler transmitral flow velocity in cardiac patients independent of systolic performanceJACC, 1992
- Nitrendipine binding in congestive heart failure due to myocardial infarction.Circulation Research, 1990
- Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failureCardiovascular Drugs and Therapy, 1990